Metabolic dysfunction–associated steatotic liver disease (MASLD) is a growing health concern in Canada, closely tied to rising rates various metabolic conditions. New and emerging treatments, such as GLP-1 receptor agonists (GLP-1s), are beginning to change how this condition is understood and managed.
In this blog, Dr. Giada Sebastiani, Professor of Medicine at McGill University Health Centre and President of the Canadian Association for the Study of the Liver, shares insights on the evolving role of GLP-1 therapies and what they could mean for the future of liver care.
GLP-1 Therapies and Liver Disease: A Turning Point in Care
Metabolic dysfunction–associated steatotic liver disease (MASLD) has become the most common liver condition in Canada and globally, affecting one in three adults. Closely linked to obesity, type 2 diabetes, and broader metabolic health, MASLD reflects a growing public health challenge that requires coordinated, multidisciplinary solutions.
Among emerging therapies, GLP-1s are generating significant attention, not only for their metabolic benefits, but also for their potential role in liver disease.
What are GLP-1 therapies, and why are they important?
GLP-1 (glucagon-like peptide-1) is a naturally occurring hormone that plays a key role in regulating blood sugar, appetite, and energy balance. GLP-1 receptor agonists are medications designed to mimic this hormone.
These therapies:
- Improve blood glucose control
- Promote meaningful and sustained weight loss
- Reduce appetite and caloric intake
- Improve insulin resistance, a key driver of MASLD
Beyond these effects, GLP-1 therapies are increasingly recognized for their organ-protective benefits, including cardiovascular and renal outcomes. This broader impact makes them particularly relevant in conditions like MASLD, which sits at the intersection of multiple chronic diseases.
What does recent research tell us about GLP-1s and liver disease?
A growing body of evidence suggests that GLP-1 therapies may play an important role in improving liver health:
- Reduction in liver fat: Consistently observed across clinical trials
- Weight loss: A central mechanism driving improvement in MASLD
- Improved metabolic profile: Including insulin resistance and glycemic control
- Benefits in liver inflammation (steatohepatitis) and fibrosis: Particularly in patients with more advanced disease
These findings are encouraging and reflect a shift toward therapies that address the root metabolic drivers of liver disease. However, it is important to recognize that:
- Much of the evidence is based on clinical trials
- Real-world evidence and long-term effects on clinical outcomes are still being defined
- Further evidence in patients with liver cirrhosis is needed
Overall, GLP-1 therapies are emerging as a key component of a comprehensive, patient-centered approach to MASLD.
What is the current status of GLP-1 therapies in Canada—and why does it matter?
In Canada, GLP-1–based therapies such as semaglutide have already transformed the management of type 2 diabetes and obesity.
More recently (December 2025), semaglutide has been approved by Health Canada for the treatment of metabolic dysfunction–associated steatohepatitis (MASH) with moderate to advanced fibrosis (stages F2–F3).
This represents a major step forward. It signals recognition that liver disease is not an isolated condition, but part of a broader cardiometabolic continuum that requires earlier identification and targeted treatment. At the same time, approval alone does not ensure access.
In Canada, real-world access depends on:
- Provincial reimbursement policies
- Eligibility criteria
- Availability of appropriate diagnostic pathways
- Awareness among healthcare providers and patients
This is particularly important because many individuals with MASLD and liver fibrosis remain undiagnosed until advanced stages. Without improved screening and referral pathways, even effective therapies may not reach those who need them most.
This moment therefore represents both a therapeutic breakthrough and a policy opportunity: to strengthen liver disease recognition, improve care pathways, and ensure equitable access across regions and populations.
Who may benefit from GLP-1 therapies?
GLP-1 therapies may be particularly beneficial for individuals who:
- Have MASLD with overweight or obesity
- Have type 2 diabetes and liver disease
- Are at higher risk of disease progression (e.g., fibrosis)
- Have not achieved sufficient improvement with lifestyle measures alone
However, these therapies are not universally indicated, and treatment decisions should be individualized based on clinical context, eligibility criteria, and patient preferences.
Looking ahead: from innovation to equitable care
GLP-1–based therapies represent an important advance in the management of MASLD and MASH. They offer the possibility of addressing not only liver disease, but also the broader metabolic conditions that drive it.
Yet their full impact will depend on how they are integrated into care.
Moving forward, priorities include:
- Improving early detection and risk stratification
- Strengthening multidisciplinary care models
- Ensuring equitable access across provinces and communities, including rural and underserved populations
- Aligning clinical innovation with health system readiness and policy frameworks
For patients, healthcare professionals, and advocates alike, this is a pivotal moment, one that calls for coordinated action to translate scientific progress into meaningful improvements in liver health across Canada.
